Biological medicines are now the largest and fastest growing segment of the pharmaceutical industry and the market is valued at over $250bn. The ability of biological medicines to target diseases very specifically makes them much more effective and much safer medicines. Yet biologics are significantly more expensive than their small molecule predecessors to manufacture. Typical costs for bringing one drug through manufacturing into the clinic are in the tens of millions.
Biopharmaceutical companies are striving to reduce the time and cost involved in bringing these medicines to the market. Finding solutions to this challenge will help transform the industry and benefit patient lives.
Scientists need new tools to better understand and optimise manufacturing. Current bioprocesses are significantly under-instrumented. To first know and then control production better, we need new fast and rich process analytics. We believe our latest innovation – a portfolio of Artificial Intelligence algoritms known as CellAi – can deliver a step change in bioprocess design and operation, giving higher yields of better quality product.
CellAi is a virtual staining approach that extracts rich cell insights from label-free, brightfield images. CellAi can predict viability, identity and stress responses. This technology will save thousands of laboratory hours and free up talented scientists to conduct significantly more tests in less time.
We are now entering an era where technology and AI will power healthcare advances. Learn more about how CellAi can shape your scientific research by getting in touch with us today.
